SELL Zydus Lifesciences — Citigroup, 12 Aug 2026

SELLZydus Lifesciences Limited

Zydus Lifesciences share price target & all analyst calls

byCitigroupHorizon: NA (inferred 1 year)12 Aug 2026via CNBC Awaaz.

Entry₹1,190Inferred

Target₹1,040

Total upside +12.61%

Stop lossNot given

CMP₹1,129.42d ago

Active+5.09%+7.92%upside left 10 mo left

Follow Citigroup for new calls(100% target hit, 52 closed calls)Get alerts Watch ZYDUSLIFE for new buy/sell callsGet alerts See 6 other Long-term calls on ZYDUSLIFE See 274 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 11:52 pm IST

7 supporting16 neutral39 opposing

Supports the SELL call (7)

Zydus Lifesciences' USFDA inspection at Ahmedabad plant concludes with 5 observations

NewsCnbc-Tv18·13 Oct · 2w ago

The USFDA concluded an inspection of Zydus Lifesciences' Moraiya manufacturing plant with 5 observations, which the company intends to address.

NSE · Press Release·13 Oct · 2w ago

The USFDA concluded an inspection of the company's Moraiya manufacturing plant with 5 observations.

BSE · Company Update·13 Oct · 2w ago

Neutral / worth noting (16)

Q2 FY27 results scheduled — board meets 04 Nov 2026

BSE · Board Meeting·In 9 days

Zydus hits 52-week high, can the optimism continue?

NewsLivemint·29 Sept · 4w ago

Weighs against the SELL call (39)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·23 Oct · 2d ago

Zydus Lifesciences' subsidiary Zylidac Bio has partnered with Prolific Machines to scale a biologics manufacturing platform to GMP production.

BSE · Company Update·21 Oct · 4d ago

Zydus Lifesciences received USFDA approval for Estradiol and Levonorgestrel Transdermal System, qualifying for 180-day competitive generic therapy exclusivity.

BSE · Company Update·21 Oct · 4d ago

Zydus Lifesciences received USFDA approval for its Estradiol and Levonorgestrel Transdermal System, qualifying for 180-day competitive generic therapy exclusivity.

NSE · Press Release·21 Oct · 4d ago

Zydus Sunshine Lifesciences has signed an agreement with the Sri Lankan Board of Investment to set up a pharmaceutical manufacturing facility.

BSE · Company Update·15 Oct · 1w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Citigroup

Every call and its outcome

SELL Zydus Lifesciences Limited — Citigroup

AI Assessment

Other calls on Zydus Lifesciences

More from Citigroup